In 2021, Dominici group reported their work on the development of selective CDK6 degraders.307 The results showed that the degradation of CDK6 was more effective than inhibition with the dual CDK4/6 inhibitor Palbociclib in suppressing Ph-positive ALL in mice, suggesting that the growth-promoting effects were CDK6 kinase-independent in Ph-positive ALL. Here, CDK4 is linked to acute lymphoblastic leukemia.